FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average h	nurden								

0.5

hours per response:

	Check this box if no longer subject to
١	Section 16. Form 4 or Form 5
J	obligations may continue. See
	Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

or Section 30(h) of the Investment Company Act of 1940 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) 2. Issuer Name and Ticker or Trading Symbol 1. Name and Address of Reporting Person AMGEN INC [AMGN] <u>Piacquad David</u> Director 10% Owner Officer (give title Other (specify below) below) 3. Date of Earliest Transaction (Month/Day/Year) (Last) (First) (Middle) SVP, Business Development 03/02/2016 ONE AMGEN CENTER DRIVE 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable (Street) **THOUSAND** 91320-1799 CA X Form filed by One Reporting Person **OAKS** Form filed by More than One Reporting (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 1. Title of Security (Instr. 3) 2. Transaction 2A. Deemed 5. Amount of 6. Ownership 7. Nature Execution Date. Transaction Securities Form: Direct of Indirect if any (Month/Day/Year) Code (Instr. 8) (D) or Indirect (Month/Day/Year) Beneficially Beneficial Owned Following (I) (Instr. 4) Ownership Reported (Instr. 4) (A) or (D) Transaction(s) Price Code ٧ Amount (Instr. 3 and 4) 03/02/2016 Common Stock 5,305 A 34,212(1)(2) D \$0 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

5. Number

Transaction

6. Date Exercisable and

Expiration Date

7. Title and

Amount of

Security (Instr. 3)		or Exercise Price of Derivative Security	(Month/Day/Year)	ir any (Month/Day/Year)	Code (Instr. 8)		Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		(Month/Day/Year)		Securities Underlying Derivative Security (Instr. 3 and 4)		Security (Instr. 5)	Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
	Code				v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					

Explanation of Responses:

1. Title of

03/03/2016 /s/ David A. Piacquad

9. Number of

8. Price of

10.

Ownership

11. Nature

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

3A. Deemed

3. Transaction

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1.} These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 510 RSUs which vest on 4/27/2016; 563 RSUs which vest in one installment of 277 on 4/26/2016 and one installment of 286 on 4/26/2017; 4,613 R\$Us which vest on 4/26/2017; 1,166 R\$Us which vest in annual installments of 384, 385 and 397 on 4/25/2016, 4/25/2017 and 4/25/2018, respectively; and 1,050 R\$Us which vest in three annual installments of 346, 347 and 357 on 1/30/2017, 1/30/2018 and 1/30/2019, respectively. Vested R\$Us will be paid in shares of the Company's common

^{2.} These shares include 371 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount.